FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023

Positive data support the potential of plixorafenib to induce deep and durable benefit for patients with BRAF-mutated (V600+) cancers In the V600+ population benefit was observed in both MAPK-inhibitor

Related Keywords

Chicago ,Illinois ,United States ,American ,Gewinn Nur ,Deric Sherman ,American Society Of Clinical Oncology ,Physician At Memorial Sloan Kettering Cancer Center ,Memorial Sloan Kettering Cancer Center ,University Of Miami Sylvester Comprehensive Cancer Center ,Linkedin ,Twitter ,Clinical Oncology ,Annual Meeting ,Stacie Shepherd ,Chief Medical Officer ,Ongoing Phase ,Macarena De La Fuente ,Associate Professor ,Miami Sylvester Comprehensive Cancer ,Associate Attending Physician ,Memorial Sloan Kettering Cancer ,Orphan Drug Designation ,Drug Administration ,Fast Track Designation ,Miami Sylvester Comprehensive Cancer Center ,Tumor Biology ,Fore ,Iotherapeutics ,Present ,Romising ,Data ,Rom ,Hase ,Trial ,Valuating ,Lixorafenib ,Ore8394 ,Patients ,Ith ,Raf ,Faltered ,Dvanced ,Olid ,Central ,Nervous ,System ,Rumors ,Disco ,023 ,